Close Menu

NEW YORK – On Thursday, Puma Biotechnology said that it entered into an exclusive licensing agreement with South Korean company Bixink Therapeutics to commercialize neratinib (Nerlynx) in South Korea.

Bixink will be responsible for seeking regulatory approval in the country, and Puma will receive upfront and milestone payments of up to $6 million, in addition to royalties on the sales of neratinib in South Korea.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.